DAX6.693-1,4%  Dow12.801-0,7%  Euro1,3200-0,7% 
ESt502.481-1,7%  Nas2.904-0,8%  Öl117,6-0,9% 
TDax769,9-0,4%  Nikkei8.947-0,6%  Gold1.721-0,5% 
Home > Aktien > Alnylam Pharmaceuticals Aktie > Nachrichten zu Alnylam Pharmaceuticals

Alnylam Pharmaceuticals Aktie [WKN: A0CBCK / ISIN: US02043Q1076]

Kurse + Charts + RealtimeNews + AnalysenFundamentalUnternehmenzugeh. WertpapiereAktion
Kurs + ChartChart (groß)News + AdhocBilanz/GuVTermineZertifikateDepot
Times + SalesChart-AnalyseAnalysenDividende/HVProfilOptionsscheineWatchlist
BörsenplätzeChartvergleichKursziele InsidertradesKnock-outsmyfinanzen
OrderbuchRealtime StuttgartRSS FeedAnalyseim ForumFondsSenden
HistorischRealtime Push  IR-DatenAnleihen
handeln

Hinweis

Auf dieser Seite finden Sie ALLE Nachrichten zur Alnylam Pharmaceuticals Inc.. Links ausgesuchte Top-Nachrichten, rechts weitere Meldungen.

Newssuche

 GO 

ALLE Nachrichten zur Alnylam Pharmaceuticals Inc.

22.06.10Sanofi-Aventis schließt Allianz mit Regulus Therapeutics
23.03.10Alnylam Completes Key Technology Transfer Objectives in its Takeda Alliance and Earns $20 Million Payment
15.03.10Alnylam and Collaborators Present New Pre-Clinical Research on RNAi Therapeutics Targeting PCSK9
09.03.10Alnylam to Webcast Presentation at the 22nd Annual ROTH OC Growth Stock Conference
03.03.10Alnylam to Webcast Presentation at Cowen and Company’s 30th Annual Health Care Conference
02.03.10Alnylam Provides Update on Ongoing Litigation Regarding the Tuschl I Patent Series
26.02.10Alnylam to Webcast RNAi Roundtable on Thursday, March 4, 2010
25.02.10Alnylam Pharmaceuticals Reports Fourth Quarter and 2009 Financial Results
25.02.10Regulus Therapeutics and GlaxoSmithKline Establish New Collaboration to Develop and Commercialize microRNA Therapeutics Targeting miR-122
24.02.10Alnylam Selected as One of the 50 Most Innovative Companies in the World by MIT’s Technology Review
22.02.10Alnylam Initiates Phase IIb Clinical Trial of ALN-RSV01 in Adult Lung Transplant Patients Infected with Respiratory Syncytial Virus (RSV) Infection
18.02.10Alnylam to Webcast Conference Call Discussing Fourth Quarter and 2009 Financial Results
08.02.10Alnylam Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Broadly Covering RNAi Therapeutics
01.02.10Alnylam to Webcast Presentation at The 12th Annual BIO CEO & Investor Conference
20.01.10BIO Ventures for Global Health Chosen as Administrator of Intellectual Property Pool Involving GSK and Alnylam as Participants
19.01.10Alnylam and Collaborators Present Data from Multiple Pre-Clinical and Clinical Programs at RNAi Keystone Symposium
19.01.10Alnylam and Collaborators Discover Additional Class of Novel Lipid Nanoparticles with Markedly Improved In Vivo Potency for RNAi Therapeutics
15.01.10Alnylam’s Kreutzer-Limmer I Patent Upheld in German Opposition Proceedings
11.01.10Alnylam Provides Key Goals and Guidance for Next 12 to 18 Months
08.01.10Alnylam and Collaborators Discover Key Mechanism for Delivery of RNAi Therapeutics
06.01.10Alnylam to Webcast Presentation at the 28th Annual J.P. Morgan Healthcare Conference
06.01.10Alnylam Receives Milestone Payment from Roche Related to Advancement of RNAi Therapeutics
29.12.09Alnylam and Collaborators at MIT Report New Pre-clinical Research on Systemic Delivery of RNAi Therapeutics
15.12.09Isis and Alnylam Announce Notice of Allowance for New U.S. Patent Application Broadly Covering RNAi Therapeutics
24.11.09Alnylam to Webcast Presentation at Piper Jaffray 21st Annual Health Care Conference
18.11.09Alnylam Presents New Pre-clinical Data on ALN-VSP, an RNAi Therapeutic for the Treatment of Liver Cancer
12.11.09Alnylam Provides Update on RNAi Pipeline, Platform, and Technology at Its R&D Day
09.11.09Alnylam to Webcast R&D Day on Thursday, November 12, 2009
05.11.09Alnylam Presents New Pre-Clinical Data on RNAi Therapeutics at Oligonucleotides Therapeutics Society (OTS) Meeting
04.11.09Alnylam Pharmaceuticals Reports Third Quarter 2009 Financial Results
04.11.09Alnylam and Roche Advance RNAi Therapeutic Collaboration Phase of Landmark 2007 Alliance
02.11.09Alnylam Presents New Pre-Clinical Data on ALN-TTR, an RNAi Therapeutic for the Treatment of Transthyretin-Mediated Amyloidosis
30.10.09Alnylam to Webcast Conference Call Discussing Third Quarter 2009 Financial Results
29.10.09Alnylam to Participate in Major Cardiovascular Disease Research Grant Awarded to Scientists at University of Pennsylvania
27.10.09Alnylam Grants KOKEN License to Kreutzer-Limmer Patents for the RNA Interference (RNAi) Research Products Market
05.10.09Alnylam to Webcast Presentation at the Fourth Annual JMP Securities Healthcare Focus Conference
16.09.09Alnylam to Webcast Presentation at UBS Global Life Sciences Conference
09.09.09Alnylam to Webcast Presentation at Morgan Stanley Global Healthcare Conference
09.09.09Alnylam Announces Allowance in Europe of New Fundamental Patent Broadly Covering RNAi Therapeutics in Oncology
03.09.09Alnylam to Webcast Presentations at the Rodman & Renshaw Global Investment Conference and the Thomas Weisel Partners Healthcare Conference 2009

Anzeige

ANZEIGE

 
Wie bewerten Sie diese Seite?
schlecht sehr gut
Aktien Prime Standard: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z DAX MDAX Dow Jones EuroStoxx

Kontakt - Impressum - Werben - Presse

finanzen.net als Startseite - Sitemap - Arbeiten bei finanzen.net - RSS-Feeds - Datenschutz - Disclaimer - Nutzungsbedingungen


Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Telekurs. Verzögerung Deutsche Börse: 15 Min., Nasdaq, NYSE: 20 Min. © 1999-2012 finanzen.net GmbH

News Aktien Kurslisten Analysen Devisen Dollarkurs Fonds Zertifikate Optionsscheine Anleihen Rohstoffe Aktien kaufen Portfolio Links Aktien China Währungsrechner Gold kaufen CFD Aktienkurse Ölpreis Leitzins Heizölpreis IPO Börsenkurse Lexikon